相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Global Genome Conformational Programming during Neuronal Development Is Associated with CTCF and Nuclear FGFR1-The Genome Archipelago Model
Brandon Decker et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Association between NER pathway gene polymorphisms and neuroblastoma risk in an eastern Chinese population
Chunlei Zhou et al.
MOLECULAR THERAPY-ONCOLYTICS (2021)
FGFR-TKI resistance in cancer: current status and perspectives
Sitong Yue et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer
Alberto Servetto et al.
CLINICAL CANCER RESEARCH (2021)
Neural crest-derived tumor neuroblastoma and melanoma share 1p13.2 as susceptibility locus that shows a long-range interaction with the SLC16A1 gene
Marianna Avitabile et al.
CARCINOGENESIS (2020)
Transcription Factors Involved in Tumorigenesis Are Over-Represented in Mutated Active DNA-Binding Sites in Neuroblastoma
Mario Capasso et al.
CANCER RESEARCH (2020)
Genetic predisposition and chromosome instability in neuroblastoma
Gian Paolo Tonini et al.
CANCER AND METASTASIS REVIEWS (2020)
Mechanisms of Efficacy of the FGFR1-3 Inhibitor AZD4547 in Pediatric Solid Tumor Models
Nikki Phanhthilath et al.
INVESTIGATIONAL NEW DRUGS (2020)
Kinome multigenic panel identified novel druggable EPHB4-V871I somatic variant in high-risk neuroblastoma
Immacolata Andolfo et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
Young K. Chae et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
19p loss is significantly enriched in older age neuroblastoma patients and correlates with poor prognosis
Vito Alessandro Lasorsain et al.
NPJ GENOMIC MEDICINE (2020)
Correlation between the genetic variants of base excision repair (BER) pathway genes and neuroblastoma susceptibility in eastern Chinese children
Zhenjian Zhuo et al.
CANCER COMMUNICATIONS (2020)
FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer (vol 15, pg 732, 2020)
Kaixuan Wang et al.
ONCOGENE (2020)
Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations
Samuel W. Brady et al.
NATURE COMMUNICATIONS (2020)
Multiplexed Droplet Digital PCR Assays for the Simultaneous Screening of Major Genetic Alterations in Tumors of the Central Nervous System
Romain Appay et al.
FRONTIERS IN ONCOLOGY (2020)
Genetic Predisposition to Solid Pediatric Cancers
Mario Capasso et al.
FRONTIERS IN ONCOLOGY (2020)
FGF/FGFR signaling pathway involved resistance in various cancer types
Yangyang Zhou et al.
JOURNAL OF CANCER (2020)
Functional characterization of full-length BARD1 strengthens its role as a tumor suppressor in neuroblastoma
Flora Cimmino et al.
JOURNAL OF CANCER (2020)
Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients
Steven M. Bray et al.
SCIENTIFIC REPORTS (2019)
GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma
Sharareh Gholamin et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
QuantumClone: clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction
Paul Deveau et al.
BIOINFORMATICS (2018)
HOTAIR Gene Polymorphisms Contribute to Increased Neuroblastoma Susceptibility in Chinese Children
Xu Yang et al.
CANCER (2018)
Systematic Functional Annotation of Somatic Mutations in Cancer
Patrick Kwok-Shing Ng et al.
CANCER CELL (2018)
Somatic mutations in specific and connected subpathways are associated with short neuroblastoma patients' survival and indicate proteins targetable at onset of disease
Maria Rosaria Esposito et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor-suppressor
Flora Cimmino et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial
Mothaffar Rimawi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Deep analysis of acquired resistance to FGFR1 inhibitor identifies MET and AKT activation and an expansion of AKT1 mutant cells
Pol Gimenez-Xavier et al.
Oncotarget (2018)
An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors
Weiyan Cheng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
The functional variant rs34330 of CDKN1B is associated with risk of neuroblastoma
Mario Capasso et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2017)
Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398
Jharna Datta et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Cancer Is to Embryology as Mutation Is to Genetics: Hypothesis of the Cancer as Embryological Phenomenon
Jaime Cofre et al.
TheScientificWorldJOURNAL (2017)
AACR Project GENIE: Powering Precision Medicine through an International Consortium
Fabrice Andre et al.
CANCER DISCOVERY (2017)
Common variants upstream of MLF1 at 3q25 and within CPZ at 4p16 associated with neuroblastoma
Lee D. McDaniel et al.
PLOS GENETICS (2017)
Cancer Is to Embryology as Mutation Is to Genetics: Hypothesis of the Cancer as Embryological Phenomenon
Jaime Cofre et al.
Scientific World Journal (2017)
Kinome expression profiling of human neuroblastoma tumors identifies potential drug targets for ultra high-risk patients
Roberta Russo et al.
CARCINOGENESIS (2017)
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers
Paul K. Paik et al.
CLINICAL CANCER RESEARCH (2017)
A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2017)
FGFR a promising druggable target in cancer: Molecular biology and new drugs
Rut Porta et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study
P. Vuylsteke et al.
ANNALS OF ONCOLOGY (2016)
Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma
M. Mohammadi et al.
CANCER GENE THERAPY (2016)
Neuroblastoma (Peripheral neuroblastic tumours)
Roberto Luksch et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
Masaru Katoh
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2016)
Evidence-Based Theory for Integrated Genome Regulation of Ontogeny-An Unprecedented Role of Nuclear FGFR1 Signaling
Michal K. Stachowiak et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2016)
An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma
Daniela Formicola et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression
Vito Alessandro Lasorsa et al.
ONCOTARGET (2016)
Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome
Olivia M. Padovan-Merhar et al.
PLOS GENETICS (2016)
CD55 is a HIF-2α marker with anti-adhesive and pro-invading properties in neuroblastoma
F. Cimmino et al.
ONCOGENESIS (2016)
Neuroblastoma
Katherine K. Matthay et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma
Konstantin Agelopoulos et al.
CLINICAL CANCER RESEARCH (2015)
Telomerase activation by genomic rearrangements in high-risk neuroblastoma
Martin Peifer et al.
NATURE (2015)
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Thomas F. Eleveld et al.
NATURE GENETICS (2015)
Mutational dynamics between primary and relapse neuroblastomas
Alexander Schramm et al.
NATURE GENETICS (2015)
Global Developmental Gene Programing Involves a Nuclear Form of Fibroblast Growth Factor Receptor-1 (FGFR1)
Christopher Terranova et al.
PLOS ONE (2015)
Inhibition of hypoxia inducible factors combined with all-trans retinoic acid treatment enhances glial transdifferentiationof neuroblastoma cells
Flora Cimmino et al.
SCIENTIFIC REPORTS (2015)
Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor beta 1 signaling in metastatic breast cancers
Michael K. Wendt et al.
BREAST CANCER RESEARCH (2014)
Nuclear translocation of FGFR1 and FGF2 in pancreatic stellate cells facilitates pancreatic cancer cell invasion
Stacey J. Coleman et al.
EMBO MOLECULAR MEDICINE (2014)
Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases
Xinhai Wan et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
FunSeq2: a framework for prioritizing noncoding regulatory variants in cancer
Yao Fu et al.
GENOME BIOLOGY (2014)
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Kristian Cibulskis et al.
NATURE BIOTECHNOLOGY (2013)
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
David T. W. Jones et al.
NATURE GENETICS (2013)
The genetic landscape of high-risk neuroblastoma
Trevor J. Pugh et al.
NATURE GENETICS (2013)
Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs
Christopher T. Saunders et al.
BIOINFORMATICS (2012)
Copynumber: Efficient algorithms for single- and multi-track copy number segmentation
Gro Nilsen et al.
BMC GENOMICS (2012)
FGFR1 cleavage and nuclear translocation regulates breast cancer cell behavior
Athina-Myrto Chioni et al.
JOURNAL OF CELL BIOLOGY (2012)
Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors
Jeffrey R. Infante et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Kai Wang et al.
NUCLEIC ACIDS RESEARCH (2010)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy
Edward F. Attiyeh et al.
GENOME RESEARCH (2009)
The Precise Sequence of FGF Receptor Autophosphorylation Is Kinetically Driven and Is Disrupted by Oncogenic Mutations
Erin D. Lew et al.
SCIENCE SIGNALING (2009)
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Adrian J. Folkes et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition
Victor D. Acevedo et al.
CANCER CELL (2007)
A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases
Huaibin Chen et al.
MOLECULAR CELL (2007)
Chemically targeting the PI3K family
Z. A. Knight et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2007)
Comparative proteomic expression profile in all-trans retinoic acid differentiated neuroblastoma cell line
Flora Cimmino et al.
JOURNAL OF PROTEOME RESEARCH (2007)
Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas
V Rand et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
分享论文
